Hemcheck has been approved for continued listing by Nasdaq, subject to the transaction with Bio Vitos being completed and other customary conditions such as updating the website after the transaction is completed.

Given this, the company description that has been produced for the process is now published and can be found on the company’s website, www.hemcheck.se. This also means that the transaction with Bio Vitos, where IP rights and capital are acquired, can be completed.

The company will quickly implement all the steps required to complete the transaction with Bio Vitos. Additional information will be shared as soon as final dates are decided.

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, acting CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.